Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients

Carlos A. Dujovne, William Harris, Raul Altman, Ron W. Overhiser, Donald M. Black

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Plasma fibrinogen and hemorheologic-hemostatic factors contribute to dyslipidemia-induced morbidity. Some of these parameters can be favorably affected when abnormal serum lipoprotein levels are corrected. Thus, we investigated whether treatment with atorvastatin would result in changes in plasma viscosity and other hemorheologic and hemostatic parameters. Twenty-two hyperlipidemic men at a university lipid clinic were treated single-blinded with atorvastatin 80 mg/day for 12 weeks to determine hemostatic-hemorheologic parameters including blood viscosity, fibrinogen levels, whole blood platelet aggregation, tissue plasminogen activator antigen, hematocrit, plasminogen activator inhibitor activity, factor VII activity, red blood cell (RBC) deformity and lipid ratio, sedimentation rate, and fasting serum lipoprotein levels. Atorvastatin treatment provided significant lowering of serum lipoprotein levels: low-density lipoprotein -53% (p = 0.0001), very low density lipoprotein -43% (p = 0.0001), and triglycerides -35% (p

Original languageEnglish (US)
Pages (from-to)350-353
Number of pages4
JournalAmerican Journal of Cardiology
Volume85
Issue number3
DOIs
StatePublished - Feb 1 2000
Externally publishedYes

Fingerprint

Hemostatics
Fibrinogen
Lipoproteins
Serum
Lipids
Plasminogen Inactivators
Blood Viscosity
Factor VII
VLDL Lipoproteins
Tissue Plasminogen Activator
Dyslipidemias
Platelet Aggregation
LDL Lipoproteins
Hematocrit
Viscosity
Fasting
Triglycerides
Blood Platelets
Erythrocytes
Morbidity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. / Dujovne, Carlos A.; Harris, William; Altman, Raul; Overhiser, Ron W.; Black, Donald M.

In: American Journal of Cardiology, Vol. 85, No. 3, 01.02.2000, p. 350-353.

Research output: Contribution to journalArticle

Dujovne, Carlos A. ; Harris, William ; Altman, Raul ; Overhiser, Ron W. ; Black, Donald M. / Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. In: American Journal of Cardiology. 2000 ; Vol. 85, No. 3. pp. 350-353.
@article{250158d718a446bd83c4ab145ec9b120,
title = "Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients",
abstract = "Plasma fibrinogen and hemorheologic-hemostatic factors contribute to dyslipidemia-induced morbidity. Some of these parameters can be favorably affected when abnormal serum lipoprotein levels are corrected. Thus, we investigated whether treatment with atorvastatin would result in changes in plasma viscosity and other hemorheologic and hemostatic parameters. Twenty-two hyperlipidemic men at a university lipid clinic were treated single-blinded with atorvastatin 80 mg/day for 12 weeks to determine hemostatic-hemorheologic parameters including blood viscosity, fibrinogen levels, whole blood platelet aggregation, tissue plasminogen activator antigen, hematocrit, plasminogen activator inhibitor activity, factor VII activity, red blood cell (RBC) deformity and lipid ratio, sedimentation rate, and fasting serum lipoprotein levels. Atorvastatin treatment provided significant lowering of serum lipoprotein levels: low-density lipoprotein -53{\%} (p = 0.0001), very low density lipoprotein -43{\%} (p = 0.0001), and triglycerides -35{\%} (p",
author = "Dujovne, {Carlos A.} and William Harris and Raul Altman and Overhiser, {Ron W.} and Black, {Donald M.}",
year = "2000",
month = "2",
day = "1",
doi = "10.1016/S0002-9149(99)00745-6",
language = "English (US)",
volume = "85",
pages = "350--353",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients

AU - Dujovne, Carlos A.

AU - Harris, William

AU - Altman, Raul

AU - Overhiser, Ron W.

AU - Black, Donald M.

PY - 2000/2/1

Y1 - 2000/2/1

N2 - Plasma fibrinogen and hemorheologic-hemostatic factors contribute to dyslipidemia-induced morbidity. Some of these parameters can be favorably affected when abnormal serum lipoprotein levels are corrected. Thus, we investigated whether treatment with atorvastatin would result in changes in plasma viscosity and other hemorheologic and hemostatic parameters. Twenty-two hyperlipidemic men at a university lipid clinic were treated single-blinded with atorvastatin 80 mg/day for 12 weeks to determine hemostatic-hemorheologic parameters including blood viscosity, fibrinogen levels, whole blood platelet aggregation, tissue plasminogen activator antigen, hematocrit, plasminogen activator inhibitor activity, factor VII activity, red blood cell (RBC) deformity and lipid ratio, sedimentation rate, and fasting serum lipoprotein levels. Atorvastatin treatment provided significant lowering of serum lipoprotein levels: low-density lipoprotein -53% (p = 0.0001), very low density lipoprotein -43% (p = 0.0001), and triglycerides -35% (p

AB - Plasma fibrinogen and hemorheologic-hemostatic factors contribute to dyslipidemia-induced morbidity. Some of these parameters can be favorably affected when abnormal serum lipoprotein levels are corrected. Thus, we investigated whether treatment with atorvastatin would result in changes in plasma viscosity and other hemorheologic and hemostatic parameters. Twenty-two hyperlipidemic men at a university lipid clinic were treated single-blinded with atorvastatin 80 mg/day for 12 weeks to determine hemostatic-hemorheologic parameters including blood viscosity, fibrinogen levels, whole blood platelet aggregation, tissue plasminogen activator antigen, hematocrit, plasminogen activator inhibitor activity, factor VII activity, red blood cell (RBC) deformity and lipid ratio, sedimentation rate, and fasting serum lipoprotein levels. Atorvastatin treatment provided significant lowering of serum lipoprotein levels: low-density lipoprotein -53% (p = 0.0001), very low density lipoprotein -43% (p = 0.0001), and triglycerides -35% (p

UR - http://www.scopus.com/inward/record.url?scp=0033958757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033958757&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(99)00745-6

DO - 10.1016/S0002-9149(99)00745-6

M3 - Article

VL - 85

SP - 350

EP - 353

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 3

ER -